What is the recommended management for postpartum hemorrhage?

Management of Postpartum Hemorrhage

Administer 5-10 IU of oxytocin (slow IV or IM) immediately at delivery for prevention, and if PPH occurs, give 1 g tranexamic acid IV within 3 hours of bleeding onset while simultaneously initiating resuscitation and identifying the underlying cause using the "4 T's" framework (Tone, Trauma, Tissue, Thrombin). 1, 2

Prevention: Active Management of Third Stage

• Prophylactic oxytocin (5-10 IU slow IV or IM) at time of shoulder delivery or immediately postpartum is the cornerstone of PPH prevention 2
• This single intervention reduces PPH incidence significantly and represents the standard of care globally
• Do NOT perform routine manual placental removal to prevent PPH—only in cases of severe uncontrollable hemorrhage 2

Early Recognition and Diagnosis

Objective blood loss assessment is critical:

• PPH is defined as >500 mL blood loss after vaginal delivery or >1000 mL after cesarean section 3
• Use quantitative measurement rather than visual estimation (which underestimates by 30-50%)
• Monitor vital signs continuously—tachycardia and hypotension are late signs
• Early clinical deterioration indicators should trigger immediate protocol activation

Immediate Management Algorithm

Step 1: Simultaneous Resuscitation and Cause Identification (First 5 minutes)

Call for help and activate massive hemorrhage protocol immediately

Resuscitation:

• Establish large-bore IV access (two lines minimum)
• Begin crystalloid fluid replacement
• Send labs: CBC, coagulation studies, type and crossmatch
• Continuous hemodynamic monitoring

Identify cause using "4 T's":

• Tone (70%): Uterine atony—most common cause
• Trauma (20%): Lacerations, hematomas, uterine rupture, inversion
• Tissue (10%): Retained placenta/membranes
• Thrombin (<1%): Coagulopathy

Step 2: Pharmacologic Management (Within 3 hours)

For uterine atony (most common):

• Bimanual uterine compression and massage immediately
• Oxytocin: If not already given, administer 10-40 IU in 1L crystalloid IV infusion
• If bleeding continues, add second-line uterotonics:
  • Methylergonovine 0.2 mg IM (contraindicated in hypertension)
  • Carboprost 250 mcg IM every 15-90 minutes (contraindicated in asthma)
  • Misoprostol 800-1000 mcg rectally

Tranexamic acid:

• 1 g IV within 1-3 hours of bleeding onset 1, 2
• The WOMAN trial (>20,000 women) demonstrated reduced mortality when given early
• Earlier administration (<3 hours) optimizes benefit—this is time-critical 1
• Reduces blood loss by 173 mL and transfusion requirements 2

Step 3: Mechanical and Surgical Interventions (If pharmacologic measures fail)

Non-surgical:

• Intrauterine balloon tamponade (Bakri balloon)—highly effective, minimally invasive first-line mechanical intervention
• Success rate 80-90% for atony refractory to uterotonics

Surgical (escalating):

• Uterine compression sutures (B-Lynch, Hayman)
• Uterine artery ligation or internal iliac artery ligation
• Hysterectomy as definitive last resort

Alternative:

• Endovascular radiologic interventions (uterine artery embolization) if available and patient stable enough for transfer

Step 4: Transfusion Strategy

For active bleeding:

• Clinical status drives transfusion decisions, not hemoglobin thresholds alone
• Activate massive transfusion protocol early if bleeding is severe
• Goal-directed transfusion with balanced blood product ratios (1:1:1 RBC:FFP:platelets)

For stable patients:

• Restrictive transfusion strategy (transfuse for Hgb <7 g/dL or symptomatic anemia)

Management of Specific Causes

Retained placenta (Tissue):

• If placenta not delivered within 30 minutes, risk of PPH increases significantly (RR 5.94) 2
• Manual removal under anesthesia
• Examine for completeness—retained fragments require curettage

Genital tract trauma (Trauma):

• Systematic inspection of cervix, vagina, perineum
• Surgical repair of lacerations under adequate anesthesia and lighting
• Rule out concealed hematomas

Uterine inversion:

• Immediate manual replacement before cervical ring contracts
• Do not remove placenta until uterus repositioned
• May require tocolysis or anesthesia for relaxation

Coagulopathy (Thrombin):

• Early involvement of hematology/transfusion medicine
• Targeted factor replacement based on laboratory values
• Consider fibrinogen concentrate if fibrinogen <200 mg/dL

Critical Pitfalls to Avoid

• Delayed tranexamic acid administration: Benefit diminishes significantly after 3 hours—give early 1
• Underestimating blood loss: Use quantitative measurement, not visual estimation
• Delayed escalation: If first-line uterotonics fail within 15-20 minutes, move to mechanical/surgical interventions
• Failure to activate protocols early: Maternal mortality increases with delayed multidisciplinary response
• Manual placental removal outside hospital: Only perform for severe uncontrollable hemorrhage 2
• Waiting for laboratory values: Begin empiric treatment based on clinical assessment

Team-Based Approach

Essential elements:

• Designated team leader for coordination
• Closed-loop communication
• Simultaneous task execution (not sequential)
• Regular drills and simulation training improve real-world performance
• Standardized institutional protocols reduce mortality by 50% 3

The evidence strongly supports early, aggressive, protocol-driven management over traditional stepwise escalation 4. The WHO recommendation for tranexamic acid based on the WOMAN trial represents the most significant recent advance in PPH management, demonstrating mortality reduction when administered within 3 hours 1.